Bidirectional link between cannabis use disorder and major depressive disorder affects over 3 million individuals

Photo by Julia Koblitz / Unsplash

Journal of psychiatric research Published June 6, 2026 Medically reviewed June 6, 2026 Study authors: Pini Alemar João, Pozzolo Pedro Maria Olivia, Leopoldo Kae, Mandaji João Vitor Guimarães, Gimenes Gi… PubMed ↗ DOI ↗ By Dr. Ji-eun Park, MD · Brain, Mind & Pain

Key Takeaway

Note bidirectional link between cannabis use disorder and major depressive disorder affecting millions.

This meta-analysis evaluates the bidirectional association between cannabis use disorder and major depressive disorder within psychiatric and community samples. The analysis included 3,279,774 individuals to assess current-diagnosis prevalence of major depressive disorder among those with cannabis use disorder and vice versa. The study did not report specific intervention details or adverse events as it focused on prevalence associations rather than treatment outcomes.

In psychiatric samples, current major depressive disorder prevalence among individuals with cannabis use disorder was elevated at 19.24% with 454,547 absolute cases. In community samples, this prevalence was elevated at 21.65% with 112,328 absolute cases. Conversely, current cannabis use disorder prevalence among individuals with major depressive disorder was substantially higher at 28.45% in psychiatric populations but lower at 4.61% in community samples.

The authors highlight differences between psychiatric and community samples, particularly the markedly higher current cannabis use disorder prevalence in patients with major depressive disorder. They emphasize the need for systematic screening across treatment settings and improved diagnostic differentiation. This is especially relevant given the overlap between depressive symptoms and cannabis withdrawal.

The study acknowledges limitations including the need to improve diagnostic differentiation regarding the overlap between depressive symptoms and cannabis withdrawal. No causality was claimed beyond the noted bidirectional association. The findings underscore the importance of recognizing these comorbidities in both clinical and community settings.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

PMID41793962

View Original Abstract ↓

OBJECTIVE: Major Depressive Disorder (MDD) and Cannabis Use Disorder (CUD) frequently co-occur, yet prevalence estimates vary widely across settings. This meta-analysis updates the evidence on the bidirectional association between MDD and CUD, emphasizing current-diagnosis subgroups, which are the most clinically relevant. METHODS: Following PRISMA and MOOSE guidelines, we systematically searched PubMed, Google Scholar, and SciELO. Random-effects models estimated current-diagnosis prevalence of MDD among individuals with CUD and of CUD among individuals with MDD. Subgroup analyses differentiated psychiatric and community samples. Sensitivity analyses (leave-one-out) and Egger's tests assessed robustness and publication bias. Meta-regressions evaluated demographic, methodological, and geographic moderators. RESULTS: In total, 55 studies comprising 3,279,774 individuals were included (454,547 and 112,328 living with CUD and MDD, respectively). Current MDD prevalence among individuals with CUD was elevated in both psychiatric samples (19.24%) and community samples (21.65%), indicating consistent comorbidity across settings. Current CUD prevalence among individuals with MDD showed stronger contextual variation, being substantially higher in psychiatric populations (28.45%) compared with community samples (4.61%). Sensitivity analyses demonstrated stable estimates across model specifications, although psychiatric samples exhibited greater variance. Studies with older populations and using ICD-10 (compared to DSM) presented higher MDD prevalence among individuals living with CUD in meta-regression models. Egger's tests revealed no consistent evidence of publication bias. CONCLUSION: Current-diagnosis estimates highlight a strong and clinically meaningful bidirectional association between MDD and CUD. Differences between psychiatric and community samples-especially the markedly higher current CUD prevalence in patients with MDD-underscore the need for systematic screening across treatment settings. Future work should improve diagnostic differentiation, particularly regarding the overlap between depressive symptoms and cannabis withdrawal.